Navigation Links
Research Report on BioClinica, Inc. as Speculative Buy
Date:11/29/2009

ATLANTA, Nov. 29 /PRNewswire/ -- The following is an investment opinion release issued by Intellivest Securities Research, Inc.

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries. A primary service is helping their clients manage, process and submit medical imaging portions of their submissions relating to their clinical trials to regulators, primarily the U.S. Food and Drug Administration and comparable European agencies, to evaluate product efficacy and safety. BioClinica has provided services to more than 130 firms in connection with over 2,000 clinical partners since its founding in 1990.

The Research Report rates BioClinica, Inc. as a Speculative Buy because the FDA and other regulators are encouraging more clinical trial data to be submitted in an electronic format. As an early mover in this area, BioClinica is well positioned to exploit this trend. BIOC has a strong balance sheet and an attractive valuation. It has no debt, adequate cash, growing positive cash flow and enjoys significant operating leverage. BioClinica's shares are currently trading around two times book value and one times revenue. It has an experienced, highly competent management team, who, along with Board members, own about 9% of outstanding shares. BIOC has worked with the world's leading bio-pharmaceutical companies including three that are Dow Jones Industrial Average components: Johnson & Johnson, Merck, and Pfizer.

BioClinica has recently completed the integration of its two most recent acquisitions both of which should be accretive in 2010. BIOC reported positive results for the third quarter ending 9/30.

The Report states that BioClinica faces a number of risks including the uncertainty facing the entire pharmaceutical industry as a result of proposed health reform legislation.

About the Report

Intellivest Securities Research, Inc.'s research is distributed by Intellivest Securities, Inc., (FINRA, SIPC, RIA, SIFMA), whose Office of Supervisory Jurisdiction is located at 1540 Chase Court, Riverdale, GA. 30296-2610. Please read the Research Report for certain disclaimers and disclosures. Daniel H. Kolber is the author of the Report and www.DowJonesMonitor.com, a daily blog that aggregates articles about the Dow Jones 30 components (not affiliated with Dow Jones). He holds these licenses: Series 24, 27, 87, 53, 4, 79, 65; is a member of the Georgia, New York, Florida and Virginia Bars, and has the B.A. from Boston University, the J.D. from University of Virginia School of Law and the Ll.M. from New York University School of Law.

Intellivest Securities Research, Inc.'s (CRD #147288) research is distributed as third party research by its affiliate, Intellivest Securities, Inc. (CRD #145022) which is a member of the Financial Industry Regulatory Authority,.

www.intellivestsecurities.com

SOURCE Intellivest Securities Research, Inc.


'/>"/>
SOURCE Intellivest Securities Research, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Research sheds light on workings of anti-cancer drug
2. Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental
3. MISSION Skincare(R) Supports GNCs Efforts To Raise Money for St. Jude Childrens Research Hospital(R)
4. Researchers identify proteins in lung cancer cells that may provide potential drug targets
5. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
6. Research Yields Clues to Severe Form of Sinusitis
7. AIDS research reveals a lack of family-planning programs in Uganda
8. Ann Taylor Stores Corp. Returns To St. Jude Childrens Research Hospitals Thanks and Giving Campaign(R) For The Third Year
9. New research shows versatility of amniotic fluid stem cells
10. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
11. Top 10 Food Tips for the Holidays from the National Foundation for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , ... March 22, 2017 , ... ... the publication of the first issue of its companion print magazine. The new ... about cosmetic surgery thanks to information provided by board-certified doctors from across the ...
(Date:3/22/2017)... ... March 22, 2017 , ... Old School Labs™, makers ... Ashley Theophane as a new Brand Ambassador. Theophane, who trained with Floyd Mayweather, made ... in 2011. He has racked up an impressive number of wins in contests in ...
(Date:3/22/2017)... Ala. (PRWEB) , ... March 22, 2017 , ... ... experience solution provider, today announced that its digital marketing solutions have enabled Children’s ... marketing investment in 24 months. , Recognizing the value of a digital ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... into a research collaboration to translate advances in basic neuroscience at the BMRI ... and beyond. The collaboration seeks to improve movement, vision, and cognition impaired by stroke, ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long Island firm ... region, is embarking on a combined charity effort with the Great Neck Breast Cancer ... 25 years, the Great Neck Breast Cancer Coalition has worked to support breast cancer ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 ... that it has completed the acquisition of Cynosure, Inc., ... $66 per share in cash. "We are ... forward to working with Michael Davin and ... in the large, rapidly growing medical aesthetics market," said ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... cannabis industry is strongly contributing to job creation. A ... and reporting for the cannabis industry, projects that by ... a quarter million jobs for American workers. The legal ... 2016, and is projected to grow at a compound ...
(Date:3/22/2017)... Minn. , March 22, 2017   Upsher-Smith Laboratories, ... Hydrochloride Capsules* USP, 25 mg, 50 mg and 75 mg, ... hydrochloride) Capsules USP. The clomipramine hydrochloride capsules ... 12 months ending December 2016, according to IMS Health. ... "Upsher-Smith has ...
Breaking Medicine Technology: